Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

COVID-19

- PMLiVE

Moderna’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

New vaccine technology could help fight future viruses and variants

The antigen technology could enhance vaccine protection against potential threats

- PMLiVE

Medscape Education’s Large Presence at IDWeek 2023

Medscape are powering education and disease state awareness in infectious diseases at #IDWeek 2023

Medscape Education Global

- PMLiVE

Nobel Prize in Medicine awarded to pair of scientists behind mRNA COVID-19 vaccines

Katalin Karikó and Drew Weissman’s findings paved the way for effective mRNA vaccines

- PMLiVE

UKHSA secures UK-based vaccine deal for future influenza pandemics

CSL Sequiris will be ready to produce over 100 million influenza pandemic vaccines

- PMLiVE

COVID-19 could be key in identifying viruses with pandemic potential

Researchers analysed major variants of concern, including the Omicron subvariants

- PMLiVE

Moderna’s XBB.1.5-adapted COVID-19 vaccine receives MHRA approval

The vaccine has been updated to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

NHS bookings for COVID-19 vaccinations open as winter programme starts early

Millions of people in England are now eligible to receive flu and COVID-19 vaccines

- PMLiVE

Moderna shares positive phase 3 results for mRNA influenza vaccine candidate

mRNA-1010 generated a strong immune response against all four WHO-recommended flu strains

- PMLiVE

US CDC recommends updated COVID-19 vaccines for autumn/winter season

Pfizer/BioNTech and Moderna’s updated vaccines will be available in the coming days

- PMLiVE

CureVac advances ‘promising’ seasonal flu mRNA vaccine to phase 2 development

The mid-stage study of the candidate is expected to begin in the fourth quarter of 2023

- PMLiVE

Moderna and Immatics announce oncology collaboration worth over $1.7bn

The agreement will focus on the development of bispecifics, cell therapies and cancer vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links